CMG Pharmaceutical

(주)CMG제약 · KOSDAQ · 058820 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩22.8bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ-19.4% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY-25.1% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩5.0bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ-68.0% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoYTurned to loss As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩45.0bn As of Jun 30, 2026 Source 1 ↗
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months48,288,869 shares As of Nov 11, 2026 Source 1 ↗, Source 2 ↗, Source 3
Potential new shares, % of shares32.6% As of Nov 11, 2026 Source 1 ↗, Source 2 ↗, Source 3, Source 4 ↗
Conversion price adjustments, last 12 months2 As of Nov 11, 2026 Source 1 ↗, Source 2

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months11 As of Nov 19, 2026
DART filings, previous 3 months13 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)0 shares As of Nov 19, 2026
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.

Trade dateInsider (role)TypeSharesPriceAmount
Oct 3, 2026Yoon Myeong-sun (Non-registered officer)Other (Reverse split)-15,264 shares——
Oct 3, 2026Chabiotech Co.,Ltd (Controlling shareholder)Other (Reverse split)-32,297,898 shares——

Annual financials

YearRevenueOperating income
2025₩105.2bn-₩3.7bn
2024₩99.1bn₩1.0bn
2023₩93.9bn₩3.0bn

Filing timeline